23andme Holding Co Stock Today
| ME Stock | USD 0.29 0.01 3.33% |
Performance0 of 100
| Odds Of DistressOver 84
|
23Andme Holding is trading at 0.29 as of the 12th of October 2024, a 3.33% down since the beginning of the trading day. The stock's lowest day price was 0.28. 23Andme Holding has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for 23Andme Holding Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of September 2024 and ending today, the 12th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of November 2020 | Category Healthcare | Classification Health Care |
23andMe Holding Co. operates as a consumer genetics testing company. The company was founded in 2006 and is headquartered in South San Francisco, California. 23Andme Holding is traded on NASDAQ Exchange in the United States. The company has 339.5 M outstanding shares of which 21.65 M shares are now sold short in the market by investors with about 7.16 days to cover all shorted shares. More on 23Andme Holding Co
Moving against 23Andme Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
23Andme Stock Highlights
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Moneta Gold Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, FinTech, Pharmaceutical Products, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Levels23Andme Holding can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand 23Andme Holding's financial leverage. It provides some insight into what part of 23Andme Holding's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
23Andme Holding Co (ME) is traded on NASDAQ Exchange in USA. It is located in 349 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 560 people. 23Andme Holding is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a market capitalization of 151.7 M. 23Andme Holding is active under Biotechnology sector as part of Health Care industry. The entity has 339.5 M outstanding shares of which 21.65 M shares are now sold short in the market by investors with about 7.16 days to cover all shorted shares.
23Andme Holding Co reports about 410.89 M in cash with (155.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check 23Andme Holding Probability Of Bankruptcy
Ownership Allocation23Andme Holding secures a total of 339.5 Million outstanding shares. 30% of 23Andme Holding outstanding shares are owned by institutions. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Hence, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check 23Andme Ownership Details
23Andme Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ensign Peak Advisors Inc | 2024-06-30 | 2.2 M | |
| Steel Partners Holdings Lp | 2024-06-30 | 2.1 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.9 M | |
| J. Safra Sarasin Holding Ag | 2024-06-30 | 1.9 M | |
| Susquehanna International Group, Llp | 2024-06-30 | 1.8 M | |
| Charles Schwab Investment Management Inc | 2024-06-30 | 1.8 M | |
| State Street Corp | 2024-06-30 | 1.2 M | |
| Amvescap Plc. | 2024-06-30 | 844.1 K | |
| Y-intercept (hong Kong) Ltd | 2024-06-30 | 808.6 K | |
| Newview Capital Partners I, Llc | 2024-06-30 | 19.5 M | |
| Vanguard Group Inc | 2024-06-30 | 15.4 M |
23Andme Holding Historical Income Statement
23Andme Stock Against Markets
23Andme Holding Corporate Management
| Anne Wojcicki | CEO, CoFounder | Profile | |
| Joseph Selsavage | Interim Officer | Profile | |
| Katie Watson | Vice Communications | Profile | |
| MB ChB | Executive Officer | Profile | |
| Wade Walke | VP Relations | Profile | |
| Jennifer Low | Head Development | Profile | |
| JD Esq | Chief Secretary | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in 23Andme Holding Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 23Andme Holding. If investors know 23Andme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 23Andme Holding listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.31) | Revenue Per Share 0.411 | Quarterly Revenue Growth (0.34) | Return On Assets (0.26) | Return On Equity (1.54) |
The market value of 23Andme Holding is measured differently than its book value, which is the value of 23Andme that is recorded on the company's balance sheet. Investors also form their own opinion of 23Andme Holding's value that differs from its market value or its book value, called intrinsic value, which is 23Andme Holding's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 23Andme Holding's market value can be influenced by many factors that don't directly affect 23Andme Holding's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 23Andme Holding's value and its price as these two are different measures arrived at by different means. Investors typically determine if 23Andme Holding is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 23Andme Holding's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.